TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05096468
Drug: S-ketamine and pregabalin
Normalized name: (S)-(-)-ketamine
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h
Study: NCT05096468
Drug: Normal saline and placebo capsule
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours
Study: NCT04826328
Drug: FX301
Normalized name: Funapide
DrugBank: Funapide (DB11769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
Study: NCT04686279
Drug: Tenofovir Douche
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Study: NCT06351644
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly oral dexamethasone 20mg
Study: NCT06618105
Drug: Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
Normalized name: albuterol sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)
Study: NCT06618105
Drug: Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
Normalized name: albuterol sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)
Study: NCT06624436
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 6mg in 10mL NaCl 0.9% i.v. bolus + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
Study: NCT06624436
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 600mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
Study: NCT06624436
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 200mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
Study: NCT04691128
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
Study: NCT04691128
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
Study: NCT05947604
Drug: Acoziborole
Normalized name: Acoziborole
DrugBank: Acoziborole (DB13086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12
Study: NCT05947604
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: • Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21
Study: NCT05947604
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
Study: NCT06625736
Drug: Xenical
Normalized name: Xenical
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients
Study: NCT06625346
Drug: Fixed-Dose Combination of Amlodipine/Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.
Study: NCT05219578
Drug: RTX-224
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX-224 monotherapy
Study: NCT04835896
Drug: M7824+paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)
Study: NCT04765553
Drug: NI-0501
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: emapalumab single i.v infusion (1 mg/kg)
Study: NCT04765553
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline single i.v infusion
Study: NCT05624866
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT05624866
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT05430048
Drug: nasal Desmopressin
Normalized name: desmopressin Nasal Solution
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
Study: NCT01304628
Drug: PL-3994
Normalized name: PL-3994
DrugBank: PL-3994 (DB15355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous PL-3994, single dose, 4 escalating dose groups
Study: NCT04156347
Drug: Episcleral Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transscleral Topotecan
Study: NCT04778787
Drug: Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
Study: NCT04991350
Drug: Intravitreal ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
Study: NCT04991350
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
Study: NCT05350124
Drug: Tocopherol
Normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin E (400 IU) capsule
Study: NCT06213519
Drug: S-1, Oxaliplatin sintilimab HIPEC
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
Study: NCT05247476
Drug: L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
Study: NCT05247476
Drug: L-T4+T3 (thyroid tablet)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
Study: NCT05241054
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
Study: NCT05241054
Drug: Nitroglycerine
Normalized name: Nitroglycerine
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
Study: NCT05241054
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
Study: NCT05241054
Drug: Atracurium Besylate
Normalized name: Atracurium Besylate
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
Study: NCT05241054
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
Study: NCT05241054
Drug: Lactated Ringers
Normalized name: lactated ringers
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
Study: NCT05241054
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
Study: NCT05101915
Drug: RESP301
Normalized name: RESP301
DrugBank: RESP301 (DB16497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled IMP delivered via nebulisation
Study: NCT05582590
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
Study: NCT04842526
Drug: Anlotinib and irinotecan combined with temozolomide
Normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
Study: NCT05813626
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
Study: NCT04988425
Drug: TNFα Monoclonal Antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
Study: NCT04988425
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 500mg of methylprednisolone immediately after admission before surgery.
Study: NCT04988425
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of the same volume of saline immediately after admission before surgery
Study: NCT02846857
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study: NCT02846857
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Study: NCT05840822
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nightly capsules prior to bed containing 0mg (placebo), 75mg cannabidiol or 150mg cannabidiol
Study: NCT04243122
Drug: Apixaban 2.5 MG Oral Tablet [ELIQUIS]
Normalized name: apixaban 2.5 MG Oral Tablet [Eliquis]
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5mg twice per day for 6 months Then treated \& followed up as per standard of care
Study: NCT04243122
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81mg once per day for 6 months Then treated \& followed up as per standard of care
Study: NCT05236621
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg pomalidomide capsules administered orally
Study: NCT05236621
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg dexamethasone tablets administered orally
Study: NCT06261684
Drug: Intralesional Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional Acyclovir in plantar warts
Study: NCT05201911
Drug: 124I-AT03
Normalized name: 124I-p5+14
DrugBank: Iodine I-124 Evuzamitide (DB18394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
Study: NCT04989985
Drug: Oxaliplatin+S-1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w
Study: NCT04989985
Drug: Sinitilimab+oxaliplatin+S-1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w
Study: NCT06340165
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anrotinib is available in 12 mg, 10 mg, and 8 mg doses. The recommended dose of Anrotinib is 12 mg taken by mouth once daily, continuously, for 2 weeks on and 1 week off, in a 21-day cycle.
Study: NCT00010686
Drug: Dietary Phytoestrogens
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06249581
Drug: AUX-001 40mg once-daily
Normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
Study: NCT06319235
Drug: IMP
Normalized name: Impact
DrugBank: Topramezone (DB14826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
Study: NCT04797325
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
Study: NCT05453045
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet administration after a meal contaning approximate 15 g of fat
Study: NCT05178485
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved drug
Study: NCT06527534
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
Study: NCT06527534
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks
Study: NCT04975100
Drug: Sarcosine and SSRI
DrugBank: Sarcosine (DB12519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
Study: NCT00000897
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05283356
Drug: Ticagrelor 60mg
Normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 60mg BID after TAVI
Study: NCT06465992
Drug: Bupivacaine Hcl 0.75% Inj
Normalized name: BUPIVACAINE HCL 0.75% INJ
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block
Study: NCT06465992
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block
Study: NCT06488794
Drug: colistimethate sodium
Normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for 3 days for eligible ventilated children starting from day 3 of mechanical ventilation.
Study: NCT05817474
Drug: lidocaine (2 %) 2 ml and tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
Study: NCT06201871
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
Study: NCT06544447
Drug: Hyaluronic acid eye drops
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Study: NCT04949139
Drug: Dextrose 5% in water
Normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reducing the sodium concentration
Study: NCT05032118
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titratable ketamine infusion + low fixed-dose propofol.
Study: NCT05032118
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care titratable propofol infusion.
Study: NCT05320016
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery
Study: NCT04842981
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
Study: NCT04842981
Drug: Sarilumab
Normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
Study: NCT05177731
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally by mouth
Study: NCT05177731
Drug: Decitabine for Injection
Normalized name: Decitabine for Injection
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05177731
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT05177731
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05177731
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally by mouth